Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (141-150 of 223) with videos related to

Pageof 23
Sort By:
Breast Cancer Research and Treatment|April 27, 2012
Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressorElizabeth Iorns, Toby M Ward, Sonja Dean, et al.
Science (New York, N.Y.)|April 4, 2020
Structural basis for allosteric PARP-1 retention on DNA breaksLevani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, et al.
Breast Cancer Research and Treatment|August 10, 2012
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibAnneleen Daemen, Denise M Wolf, James E Korkola, et al.
Journal of Clinical Medicine|January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome SequencingIrene Y Chong, Naureen Starling, Alistair Rust, et al.
Scientific Reports|January 19, 2019
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitorsMalini Menon, Richard Elliott, Leandra Bowers, et al.
Nature Communications|December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
Cancer Discovery|February 13, 2014
An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressorNirupa Murugaesu, Marjan Iravani, Antoinette van Weverwijk, et al.
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Pageof 23

Showing results (141-150 of 223) with videos related to

Sort By:
Pageof 23
Breast Cancer Research and Treatment|April 27, 2012
Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressorElizabeth Iorns, Toby M Ward, Sonja Dean, et al.
Science (New York, N.Y.)|April 4, 2020
Structural basis for allosteric PARP-1 retention on DNA breaksLevani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, et al.
Breast Cancer Research and Treatment|August 10, 2012
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibAnneleen Daemen, Denise M Wolf, James E Korkola, et al.
Journal of Clinical Medicine|January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome SequencingIrene Y Chong, Naureen Starling, Alistair Rust, et al.
Scientific Reports|January 19, 2019
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitorsMalini Menon, Richard Elliott, Leandra Bowers, et al.
Nature Communications|December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
Cancer Discovery|February 13, 2014
An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressorNirupa Murugaesu, Marjan Iravani, Antoinette van Weverwijk, et al.
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Pageof 23